Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Rating of “Reduce” by Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has been given a consensus recommendation of “Reduce” by the fourteen ratings firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $406.60.

MEDP has been the topic of several research analyst reports. UBS Group cut Medpace from a “neutral” rating to a “sell” rating and raised their price objective for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft increased their target price on Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research report on Wednesday, July 23rd. Robert W. Baird lifted their price objective on shares of Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Barclays lifted their price objective on shares of Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 23rd. Finally, Truist Financial boosted their price target on shares of Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a research report on Wednesday, July 23rd.

Insider Transactions at Medpace

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.14, for a total value of $3,376,050.00. Following the sale, the vice president directly owned 57,500 shares in the company, valued at approximately $25,883,050. The trade was a 11.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of Medpace stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total value of $772,896.48. Following the completion of the transaction, the director directly owned 10,197 shares in the company, valued at $4,742,012.88. This represents a 14.01% decrease in their position. The disclosure for this sale can be found here. Insiders sold 115,070 shares of company stock valued at $52,085,751 in the last quarter. 20.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Medpace

Institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group grew its stake in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares in the last quarter. Whittier Trust Co. grew its stake in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after acquiring an additional 35 shares in the last quarter. Employees Retirement System of Texas purchased a new position in Medpace during the 2nd quarter valued at about $36,000. Finally, Colonial Trust Co SC grew its stake in Medpace by 150.0% during the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company’s stock valued at $58,000 after acquiring an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.5%

Medpace stock opened at $475.51 on Monday. The stock has a market cap of $13.36 billion, a P/E ratio of 35.35, a price-to-earnings-growth ratio of 2.99 and a beta of 1.44. The stock has a 50 day moving average of $395.75 and a 200-day moving average of $339.36. Medpace has a 52 week low of $250.05 and a 52 week high of $501.30.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to analysts’ expectations of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business’s revenue was up 14.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities analysts predict that Medpace will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.